EBOLA VIRUS AND MARBURG VIRUS GLYCOPROTEIN MUCIN-LIKE DOMAIN REPLACEMENT EXPRESSION SYSTEM USED AS NEW VACCINE APPROACHES

摘要

We have developed a series of Ebola virus envelope glycoprotein (EboGP)- based chimeric fusion proteins that are still able to maintain an efficient EboGP- mediated virus entry in various cell types including human antigen-presenting cells (APCs) while presenting large viral polypeptides, such as HIV Env v3-v5 domain (as large as 241 aa), at the apex and the sides of each EboGP monomer to elicit robust host immune responses. This invention demonstrates the feasibility of an EboGP- based chimeric fusion technology as a novel vaccine approach against different microbial pathogens, including that in human and animals, and against cancers.